Oncopeptides’ Pepaxti has been granted marketing authorization in the UK Regulatory
November 11, 2022
STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti[®] (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK
Read more
Oncopeptides publishes Q3 report 2022 Regulatory
November 9, 2022
STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022
Read more
Oncopeptides announces the market potential for Pepaxti in Europe Regulatory
November 9, 2022
STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential for Pepaxti[®] in Europe. The potential assumes that the Company´s pending type 2 variation submission to the European Medicines Agency based on OCEAN data, will be approved by the agency, and enable patients with relapsed refractory multiple myeloma access to the drug in an earlier treatment line. Furthermore, the market potential assumes that price negotiations will reflect the degree of innovation of the drug and the clinical benefit to the patients
Read more
Number of shares and votes in Oncopeptides Regulatory
October 31, 2022
STOCKHOLM — October 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 3,940,607 new class C shares in accordance with the shareholder program Board SHP 2022 and the incentive program Co-worker LTIP 2022 adopted by the annual general meeting on June 28, 2022. Before the share issue, the total number of outstanding shares and votes in Oncopeptides amounted to 90,368,660. As a result of the share issue, the number of outstanding shares in Oncopeptides has increased by 3,940,607 shares, corresponding to 394,060.7 votes. As of today, the total number of outstanding shares in Oncopeptides amounts to 94,309,267 shares, of which 90,368,660 are ordinary shares and 3,940,607 are class C shares. The number of votes in Oncopeptides as of today amounts to 90,762,720.7. The share capital has increased by approximately SEK 437,845.24 from approximately SEK 10,040,962.63 to approximately SEK 10,478,807.87
Read more
Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen Regulatory
October 26, 2022
STOCKHOLM — October 26, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces data from the phase 3 LIGHTHOUSE study that further confirms the clinical benefit of melflufen in patients with relapsed refractory multiple myeloma (RRMM). The LIGHTHOUSE study investigated the efficacy and safety of the combination of melflufen plus daratumumab subcutaneous (sc) plus dexamethasone in comparison with daratumumab sc. (with supportive dexamethasone) in patients who were refractory to at least an immunomodulatory agent and a proteasome inhibitor or have received at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent
Read more
Issue and re-purchase of class C shares for shareholder program and incentive program Regulatory
October 20, 2022
STOCKHOLM — October 20, 2022 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022, to issue and immediately thereafter re-purchase a total of 3,940,607 class C shares. The shares are issued and re-purchased in accordance with the shareholder program and the incentive program which were adopted by the Annual General Meeting held on June 28, 2022 (“Board SHP 2022” and “Co-worker LTIP 2022” respectively)
Read more
Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market
October 3, 2022
STOCKHOLM — October 3, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted the AMNOG dossier to “The Federal Joint Committee” (G-BA) in Germany. This initiates the commercial launch of Pepaxti[®] (melphalan flufenamide) and thus Germany will be the first market in Europe where the drug is launched
Read more
Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ) Regulatory
September 23, 2022
Stockholm, Sweden – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022. At the Extraordinary General Meeting, the following principal resolution was passed
Read more
Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC Regulatory
September 23, 2022
STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto[®] (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population. Pepaxto is indicated in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM), who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody
Read more
Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published
September 20, 2022
STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration (FDA), has published the Briefing Book for the Oncologic Drugs Advisory Committee (ODAC) meeting on September 22, 2022. The purpose of the meeting is to obtain the advisory committee´s input regarding the benefit/risk of Pepaxto[®] (melphalan flufenamide, also called melflufen) for the currently indicated patient population
Read more